Autopsy report · NCT00705549

Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

“Due to poor accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 3 years 7 months before it stopped.
• 88 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hellenic Oncology Research Group

Sponsor type

University, hospital or other

Conditions

Non-Small-Cell Lung Cancer

Interventions

Gemcitabine; Cisplatin; Docetaxel; Cisplatin; Vinorelbine; Pemetrexate

Participants

88

Sites

9

Countries

Greece

Trials that died the same way

• A Study of Olaparib and Durvalumab in Prostate Cancer
  “Due to low accrual” (93% match in meaning)
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (84% match in meaning)
• Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
  “Poor accrual” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.